NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.70 -0.87 (-1.12%) GOLD FUTURES
2,344.40 -48.50 (-2.03%) DOW
39,269.56 -401.48 (-1.01%) Bitcoin GBP
53,461.35 -1,847.18 (-3.34%)
EDIT Jan 2025 7.500 put
| Previous close | 2.3500 |
| Open | 2.3500 |
| Bid | 2.4000 |
| Ask | 2.5500 |
| Strike | 7.50 |
| Expiry date | 2025-01-17 |
| Day's range | 2.3500 - 2.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 475 |
GuruFocus.comEVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024.
GuruFocus.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
GlobeNewswireEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
